Literature DB >> 11291675

Invasive pulmonary aspergillosis associated with infliximab therapy.

A Warris, A Bjørneklett, P Gaustad.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11291675

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  44 in total

1.  Involvement of toll-like receptor 2 in experimental invasive pulmonary aspergillosis.

Authors:  Viviane Balloy; Mustapha Si-Tahar; Osamu Takeuchi; Bruno Philippe; Marie-Anne Nahori; Myriam Tanguy; Michel Huerre; Shizuo Akira; Jean-Paul Latgé; Michel Chignard
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

Review 2.  Pneumocystis carinii pneumonia with oral candidiasis after infliximab therapy for Crohn's disease.

Authors:  Nirmal Kaur; Thomas C Mahl
Journal:  Dig Dis Sci       Date:  2004-09       Impact factor: 3.199

Review 3.  Listeria-associated arthritis in a patient undergoing etanercept therapy: case report and review of the literature.

Authors:  Georg Schett; Petra Herak; Winfried Graninger; Josef S Smolen; Martin Aringer
Journal:  J Clin Microbiol       Date:  2005-05       Impact factor: 5.948

4.  Transient neutralization of tumor necrosis factor alpha can produce a chronic fungal infection in an immunocompetent host: potential role of immature dendritic cells.

Authors:  Amy C Herring; Nicole R Falkowski; Gwo-Hsiao Chen; Rod A McDonald; Galen B Toews; Gary B Huffnagle
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

Review 5.  Aspergillus fumigatus: principles of pathogenesis and host defense.

Authors:  Tobias M Hohl; Marta Feldmesser
Journal:  Eukaryot Cell       Date:  2007-09-21

Review 6.  Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease.

Authors:  D C Sadowski; C N Bernstein; A Bitton; K Croitoru; R N Fedorak; A Griffiths
Journal:  Can J Gastroenterol       Date:  2009-03       Impact factor: 3.522

7.  Clinical course of patients with Behçet's uveitis following discontinuation of infliximab therapy.

Authors:  Tatsushi Kawaguchi; Yuko Kawazoe; Koju Kamoi; Masaru Miyanaga; Hiroshi Takase; Sunao Sugita; Manabu Mochizuki
Journal:  Jpn J Ophthalmol       Date:  2013-10-16       Impact factor: 2.447

8.  Pulmonary aspergillosis after treatment with infliximab in Still's disease and a literature review of Still's disease and pulmonary aspergillosis.

Authors:  Emrah Şeyhoğlu; Abdülsamet Erden; Levent Kılıç; Ömer Karadağ; Sevtap Arıkan Akdağlı; Ali Akdoğan; Umut Kalyoncu
Journal:  Eur J Rheumatol       Date:  2018-03

Review 9.  Biologic treatments for systemic rheumatic diseases.

Authors:  Y Shirota; G G Illei; N P Nikolov
Journal:  Oral Dis       Date:  2008-02-14       Impact factor: 3.511

10.  Listeria meningitis complicating infliximab treatment for Crohn's disease.

Authors:  Geoffrey Williams; Asad A Khan; Franzjosef Schweiger
Journal:  Can J Infect Dis Med Microbiol       Date:  2005-09       Impact factor: 2.471
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.